Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Before any new drug or diagnostic technology can be used widely, it must pass through a series of structured studies designed to answer specific questions. The milestone highlighted in Quantum BioPharma’s announcement is that patient enrollment in a key pilot study has reached its halfway mark. Preliminary analyses show a robust signal in acute MS lesions, along with potential sensitivity to gray matter lesions. Clinical studies are among the most demanding and consequential undertakings in medicine. They require years of planning, careful patient selection,…